Helen McShane

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3413709/publications.pdf

Version: 2024-02-01

219 papers	12,548 citations	26630 56 h-index	30087 103 g-index
234 all docs	234 docs citations	234 times ranked	9754 citing authors

#	Article	IF	Citations
1	Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet, The, 2013, 381, 1021-1028.	13.7	903
2	Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Medicine, 2004, 10, 1240-1244.	30.7	538
3	COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychological Medicine, 2022, 52, 3127-3141.	4.5	524
4	Rapid Detection of <i>Mycobacterium tuberculosis</i>Infection by Enumeration of Antigen-specific T Cells. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 824-828.	5.6	410
5	Enhanced Immunogenicity and Protective Efficacy Against <i>Mycobacterium tuberculosis</i> of Bacille Calmette-GueÌrin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara. Journal of Immunology, 2003, 171, 1602-1609.	0.8	345
6	Direct Ex Vivo Analysis of Antigen-Specific IFN-Î³-Secreting CD4 T Cells in <i>Mycobacterium tuberculosis</i>-Infected Individuals: Associations with Clinical Disease State and Effect of Treatment. Journal of Immunology, 2001, 167, 5217-5225.	0.8	329
7	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine, 2022, 28, 1031-1041.	30.7	281
8	Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against <i>Mycobacterium tuberculosis</i> Aerosol Challenge in Mice. Journal of Immunology, 2008, 181, 4955-4964.	0.8	269
9	Viral Booster Vaccines Improve <i>Mycobacterium bovis</i> BCG-Induced Protection against Bovine Tuberculosis. Infection and Immunity, 2009, 77, 3364-3373.	2.2	237
10	T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nature Communications, 2016, 7, 11290.	12.8	236
11	Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis. Infection and Immunity, 2001, 69, 681-686.	2.2	213
12	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Journal of General Virology, 2004, 85, 911-919.	2.9	206
13	Immunisation with BCG and recombinant MVA85A induces longâ€lasting, polyfunctional <i>Mycobacterium tuberculosis</i>â€specific CD4⁺ memory T lymphocyte populations. European Journal of Immunology, 2007, 37, 3089-3100.	2.9	206
14	MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques. PLoS ONE, 2009, 4, e5264.	2.5	186
15	Effects of different types of written vaccination information on COVID-19 vaccine hesitancy in the UK (OCEANS-III): a single-blind, parallel-group, randomised controlled trial. Lancet Public Health, The, 2021, 6, e416-e427.	10.0	184
16	Modified vaccinia Ankaraâ€expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells. European Journal of Immunology, 2010, 40, 279-290.	2.9	171
17	The human immune response to tuberculosis and its treatment: a view from the blood. Immunological Reviews, 2015, 264, 88-102.	6.0	168
18	Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infectious Diseases, The, 2014, 14, 939-946.	9.1	164

#	Article	IF	Citations
19	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. Journal of Infectious Diseases, 2008, 198, 544-552.	4.0	155
20	Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis, 2005, 85, 29-38.	1.9	154
21	Antibodies and tuberculosis. Tuberculosis, 2016, 101, 102-113.	1.9	131
22	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2015, 3, 190-200.	10.7	122
23	Protective Immunity against Mycobacterium tuberculosis Induced by Dendritic Cells Pulsed with both CD8+- and CD4+-T-Cell Epitopes from Antigen 85A. Infection and Immunity, 2002, 70, 1623-1626.	2.2	119
24	Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine, 2006, 24, 417-425.	3.8	117
25	Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis, 2005, 85, 47-52.	1.9	114
26	Tuberculosis vaccines: beyond bacille Calmetteâ€"GuÃ©rin. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2782-2789.	4.0	110
27	Association of Human Antibodies to Arabinomannan With Enhanced Mycobacterial Opsonophagocytosis and Intracellular Growth Reduction. Journal of Infectious Diseases, 2016, 214, 300-310.	4.0	110
28	Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respiratory Medicine,the, 2017, 5, 282-290.	10.7	110
29	Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in <i>Mycobacterium tuberculosis</i>â€"infected Individuals. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733.	5.6	107
30	Prime-boost immunisation strategies for tuberculosis. Microbes and Infection, 2005, 7, 962-967.	1.9	103
31	A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis, 2014, 94, 105-110.	1.9	103
32	A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-GuÃ©rin. Journal of Infectious Diseases, 2012, 205, 1035-1042.	4.0	99
33	Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 209, 500-509.	4.0	99
34	Synergistic DNAâ€"MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine, 2006, 24, 4554-4561.	3.8	97
35	High frequencies of circulating IFN-Î³-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope inM. tuberculosis-infected subjects without disease. European Journal of Immunology, 2000, 30, 2713-2721.	2.9	94
36	Injection fears and COVID-19 vaccine hesitancy. Psychological Medicine, 2023, 53, 1185-1195.	4.5	94

#	Article	IF	Citations
37	Progress and challenges in TB vaccine development. F1000Research, 2018, 7, 199.	1.6	93
38	Tuberculosis vaccines in clinical trials. Expert Review of Vaccines, 2011, 10, 645-658.	4.4	90
39	The Humoral Immune Response to BCG Vaccination. Frontiers in Immunology, 2019, 10, 1317.	4.8	86
40	Inhibition of Mycobacterial Growth<i>In Vitro</i>following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG. Vaccine Journal, 2013, 20, 1683-1689.	3.1	85
41	Delaying Bacillus Calmette-GuÃ©rin Vaccination from Birth to 4 1/2 Months of Age Reduces Postvaccination Th1 and IL-17 Responses but Leads to Comparable Mycobacterial Responses at 9 Months of Age. Journal of Immunology, 2010, 185, 2620-2628.	0.8	84
42	Co-infection with HIV and TB: double trouble. International Journal of STD and AIDS, 2005, 16, 95-101.	1.1	83
43	Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo. Blood, 2014, 124, e33-e44.	1.4	83
44	Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. PLoS Medicine, 2008, 5, e145.	8.4	82
45	The association between the ratio of monocytes:lymphocytes at age 3Âmonths and risk of tuberculosis (TB) in the first two years of life. BMC Medicine, 2014, 12, 120.	5.5	80
46	The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses. PLoS ONE, 2014, 9, e87340.	2.5	79
47	A Phase IIa Trial of the New Tuberculosis Vaccine, MVA85A, in HIV- and/or <i>Mycobacterium tuberculosis</i>â€“infected Adults. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 769-778.	5.6	78
48	Dose-Finding Study of the Novel Tuberculosis Vaccine, MVA85A, in Healthy BCG-Vaccinated Infants. Journal of Infectious Diseases, 2011, 203, 1832-1843.	4.0	75
49	Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination. Journal of Infectious Diseases, 2014, 209, 1259-1268.	4.0	73
50	Vaccination against tuberculosis: How can we better BCG?. Microbial Pathogenesis, 2013, 58, 2-16.	2.9	71
51	Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis, 2014, 94, 226-237.	1.9	71
52	Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. PLoS ONE, 2015, 10, e0138042.	2.5	71
53	Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine. Infection and Immunity, 2018, 86, .	2.2	70
54	Identification of antigens presented by MHC for vaccines against tuberculosis. Npj Vaccines, 2020, 5, 2.	6.0	69

#	Article	IF	Citations
55	Online Social Endorsement and Covid-19 Vaccine Hesitancy in the United Kingdom. Social Media and Society, 2021, 7, 205630512110088.	3.0	64
56	Impaired IFN-Î³-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Aids, 2006, 20, 821-829.	2.2	63
57	Aerosol immunisation for TB: matching route of vaccination to route of infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 175-181.	1.8	62
58	Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes. EBioMedicine, 2015, 2, 1619-1626.	6.1	61
59	In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy. Vaccine, 2016, 34, 4656-4665.	3.8	61
60	Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A. PLoS ONE, 2009, 4, e5934.	2.5	61
61	Why donâ€™t we have an effective tuberculosis vaccine yet?. Expert Review of Vaccines, 2016, 15, 1009-1013.	4.4	60
62	Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Î” <i>ureC hly</i> ⁺ <i>Mycobacterium bovis</i> BCG and Modified Vaccinia Virus Ankara Expressing <i>M. tuberculosis</i> Antigen 85A against Murine Tuberculosis. Infection and Immunity, 2009, 77, 622-631.	2.2	59
63	A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime â€“ MVA85A boost in healthy UK adults. Vaccine, 2020, 38, 779-789.	3.8	58
64	Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Medicine, 2019, 16, e1002790.	8.4	57
65	Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials. PLoS ONE, 2007, 2, e1052.	2.5	57
66	Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. Lancet Infectious Diseases, The, 2006, 6, 522-528.	9.1	55
67	Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy,<i>Mycobacterium bovis</i>BCG-Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A. Vaccine Journal, 2010, 17, 1066-1073.	3.1	50
68	Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants. Science Translational Medicine, 2011, 3, 88ra56.	12.4	50
69	Enhancing the Biological Relevance of Machine Learning Classifiers for Reverse Vaccinology. International Journal of Molecular Sciences, 2017, 18, 312.	4.1	50
70	Vaccine Platform for Prevention of Tuberculosis and Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1 through Breastfeeding. Journal of Virology, 2007, 81, 9408-9418.	3.4	47
71	A comparison of IFNÎ³ detection methods used in tuberculosis vaccine trials. Tuberculosis, 2008, 88, 631-640.	1.9	47
72	Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery. Vaccine, 2013, 31, 1026-1033.	3.8	47

#	Article	IF	Citations
73	Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis. PLoS ONE, 2009, 4, e7972.	2.5	46
74	Insights and challenges in tuberculosis vaccine development. Lancet Respiratory Medicine,the, 2019, 7, 810-819.	10.7	46
75	Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M.Âtb). Tuberculosis, 2013, 93, 551-557.	1.9	45
76	Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa. PLoS ONE, 2008, 3, e2921.	2.5	45
77	The Tuberculin Skin Test (TST) Is Affected by Recent BCG Vaccination but Not by Exposure to Non-Tuberculosis Mycobacteria (NTM) during Early Life. PLoS ONE, 2010, 5, e12287.	2.5	44
78	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. Frontiers in Immunology, 2017, 8, 1203.	4.8	44
79	Prime-boost immunization strategies for infectious diseases. Current Opinion in Molecular Therapeutics, 2002, 4, 23-7.	2.8	44
80	CD8+ T cell-mediated suppression of intracellularMycobacterium tuberculosis growth in activated human macrophages. European Journal of Immunology, 2003, 33, 3293-3302.	2.9	43
81	Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infection. Scientific Reports, 2018, 8, 14480.	3.3	43
82	A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open, 2011, 1, e000223-e000223.	1.9	42
83	Cytomegalovirus infection is a risk factor for tuberculosis disease in infants. JCI Insight, 2019, 4, .	5.0	42
84	The Cross-Species Mycobacterial Growth Inhibition Assay (MGIA) Project, 2010â€"2014. Vaccine Journal, 2017, 24, .	3.1	41
85	Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunology, 2010, 11, 35.	2.2	40
86	Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults. Vaccine, 2012, 30, 5616-5624.	3.8	40
87	Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85A. PLoS ONE, 2011, 6, e23463.	2.5	39
88	The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assays. Scientific Reports, 2017, 7, 43478.	3.3	39
89	SARS-CoV-2 Human Challenge Studies â€" Establishing the Model during an Evolving Pandemic. New England Journal of Medicine, 2021, 385, 961-964.	27.0	39
90	A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults. Vaccine, 2016, 34, 1412-1421.	3.8	37

#	Article	IF	Citations
91	Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. Expert Review of Vaccines, 2019, 18, 1271-1284.	4.4	37
92	Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine Efficacy. PLoS ONE, 2011, 6, e19840.	2.5	36
93	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 573-575.	2.1	36
94	Gene Expression and Cytokine Profile Correlate With Mycobacterial Growth in a Human BCG Challenge Model. Journal of Infectious Diseases, 2015, 211, 1499-1509.	4.0	36
95	Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis, 2013, 93, 143-149.	1.9	35
96	A Multi-Antigenic Adenoviral-Vectored Vaccine Improves BCG-Induced Protection of Goats against Pulmonary Tuberculosis Infection and Prevents Disease Progression. PLoS ONE, 2013, 8, e81317.	2.5	33
97	A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults. PLoS ONE, 2015, 10, e0141687.	2.5	33
98	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial. Clinical Infectious Diseases, 2018, 66, 554-563.	5.8	32
99	Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respiratory Medicine,the, 2022, 10, 255-266.	10.7	32
100	WHO preferred product characteristics for new vaccines against tuberculosis. Lancet Infectious Diseases, The, 2018, 18, 828-829.	9.1	31
101	Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK. F1000Research, 2018, 7, 461.	1.6	30
102	Development of a BCG challenge model for the testing of vaccine candidates against tuberculosis in cattle. Vaccine, 2014, 32, 5645-5649.	3.8	29
103	Human challenge trials in vaccine development, Rockville, MD, USA, September 28â€“30, 2017. Biologicals, 2019, 61, 85-94.	1.4	29
104	Tuberculosis vaccines: progress and challenges. Trends in Pharmacological Sciences, 2011, 32, 601-606.	8.7	28
105	Optimization of a Human Bacille Calmette-GuÃ©rin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity. Journal of Infectious Diseases, 2016, 213, 824-830.	4.0	28
106	Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis Infection. Frontiers in Immunology, 2018, 9, 2893.	4.8	28
107	Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. Journal of Immunological Methods, 2019, 469, 1-10.	1.4	28
108	The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Neglected Tropical Diseases, 2017, 11, e0005440.	3.0	28

#	Article	IF	Citations
109	Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis. PLoS ONE, 2011, 6, e20067.	2.5	27
110	A new tool for tuberculosis vaccine screening: Ex vivo Mycobacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine model of tuberculosis. BMC Infectious Diseases, 2016, 16, 412.	2.9	27
111	Roles for Treg Expansion and HMGB1 Signaling through the TLR1-2-6 Axis in Determining the Magnitude of the Antigen-Specific Immune Response to MVA85A. PLoS ONE, 2013, 8, e67922.	2.5	27
112	Heterologous vaccination against human tuberculosis modulates antigenâ€specific <scp>CD</scp>4⁺<scp>T</scp>â€cell function. European Journal of Immunology, 2013, 43, 2409-2420.	2.9	26
113	Human Immunodeficiency Virus Infection Impairs Th1 and Th17 Mycobacterium tuberculosisâ€“Specific T-Cell Responses. Journal of Infectious Diseases, 2018, 217, 1782-1792.	4.0	26
114	Towards new TB vaccines. Seminars in Immunopathology, 2020, 42, 315-331.	6.1	26
115	Developing an improved vaccine against tuberculosis. Expert Review of Vaccines, 2004, 3, 299-306.	4.4	25
116	TB vaccine development: where are we and why is it so difficult?. Thorax, 2015, 70, 299-301.	5.6	25
117	Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK. F1000Research, 2018, 7, 461.	1.6	25
118	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response. BMC Infectious Diseases, 2014, 14, 314.	2.9	24
119	Clinical Testing of Tuberculosis Vaccine Candidates. Microbiology Spectrum, 2016, 4, .	3.0	24
120	Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccines. Tuberculosis, 2018, 108, 99-105.	1.9	24
121	Regulation of mycobacterial infection by macrophage Gch1 and tetrahydrobiopterin. Nature Communications, 2018, 9, 5409.	12.8	24
122	Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. Frontiers in Immunology, 2019, 10, 2983.	4.8	24
123	Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-Î²1. Vaccine, 2008, 26, 5269-5275.	3.8	23
124	The Role of Clinical Symptoms in the Diagnosis of Intrathoracic Tuberculosis in Young Children. Pediatric Infectious Disease Journal, 2015, 34, 1157-1162.	2.0	23
125	Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection. PLoS ONE, 2012, 7, e50447.	2.5	23
126	Tuberculin Skin Testing and Treatment Modulates Interferon-Gamma Release Assay Results for Latent Tuberculosis in Migrants. PLoS ONE, 2014, 9, e97366.	2.5	23

#	Article	IF	Citations
127	Susceptibility to tuberculosis - the importance of the pathogen as well as the host. Clinical and Experimental Immunology, 2003, 133, 20-21.	2.6	21
128	Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults. Human Vaccines and Immunotherapeutics, 2013, 9, 50-62.	3.3	21
129	Editorial Commentary: Understanding BCG Is the Key to Improving It. Clinical Infectious Diseases, 2014, 58, 481-482.	5.8	21
130	Identification of Antigens Specific to Non-Tuberculous Mycobacteria: The Mce Family of Proteins as a Target of T Cell Immune Responses. PLoS ONE, 2011, 6, e26434.	2.5	20
131	Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A. BMC Infectious Diseases, 2014, 14, 660.	2.9	20
132	A review of clinical models for the evaluation of human TB vaccines. Human Vaccines and Immunotherapeutics, 2016, 12, 1177-1187.	3.3	20
133	Local Pulmonary Immunological Biomarkers in Tuberculosis. Frontiers in Immunology, 2021, 12, 640916.	4.8	20
134	Cholera Toxin Enhances Vaccine-Induced Protection against Mycobacterium Tuberculosis Challenge in Mice. PLoS ONE, 2013, 8, e78312.	2.5	20
135	Replacing, reducing and refining the use of animals in tuberculosis vaccine research. ALTEX: Alternatives To Animal Experimentation, 2017, 34, 157-166.	1.5	20
136	Evaluation of XpertÂ® MTB/RIF Assay in Induced Sputum and Gastric Lavage Samples from Young Children with Suspected Tuberculosis from the MVA85A TB Vaccine Trial. PLoS ONE, 2015, 10, e0141623.	2.5	19
137	Current approaches toward identifying a correlate of immune protection from tuberculosis. Expert Review of Vaccines, 2019, 18, 43-59.	4.4	18
138	Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2018, 9, 1529.	4.8	16
139	The next 10 years for tuberculosis vaccines: do we have the right plans in place?. Expert Review of Vaccines, 2013, 12, 443-451.	4.4	15
140	Process of Assay Selection and Optimization for the Study of Case and Control Samples from a Phase IIb Efficacy Trial of a Candidate Tuberculosis Vaccine, MVA85A. Vaccine Journal, 2014, 21, 1005-1011.	3.1	15
141	Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. PLoS ONE, 2018, 13, e0201205.	2.5	15
142	Tuberculosis vaccines in the era of Covid-19 â€“ what is taking us so long?. EBioMedicine, 2022, 79, 103993.	6.1	15
143	Distinct blood transcriptomic signature of treatment in latent tuberculosis infected individuals at risk of developing active disease. Tuberculosis, 2021, 131, 102127.	1.9	13
144	Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model. PLoS ONE, 2018, 13, e0191038.	2.5	13

#	Article	IF	Citations
145	Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. Vaccine, 2021, 39, 1452-1462.	3.8	12
146	Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) NaÃ¯ve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects. PLoS ONE, 2013, 8, e67177.	2.5	11
147	Controlled Human Infection Models: Is it Really Feasible to Give People Tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1180-1181.	5.6	11
148	A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development. Tuberculosis, 2017, 106, 118-122.	1.9	10
149	Cytokines and Chemokines inMycobacterium tuberculosisInfection. , 2017, , 33-72.		10
150	Lessons from the pandemic on the value of research infrastructure. Health Research Policy and Systems, 2021, 19, 54.	2.8	10
151	Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination. Frontiers in Immunology, 2021, 12, 798207.	4.8	10
152	Tuberculosis vaccines: current status and future prospects. Expert Opinion on Emerging Drugs, 2006, 11, 207-215.	2.4	9
153	A New Vaccine for Tuberculosis: The Challenges of Development and Deployment. Journal of Bioethical Inquiry, 2009, 6, 219-228.	1.5	9
154	Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatric Infectious Disease Journal, 2015, 34, 1218-1222.	2.0	9
155	Markers of achievement for assessing and monitoring gender equity in a UK National Institute for Health Research Biomedical Research Centre: A two-factor model. PLoS ONE, 2020, 15, e0239589.	2.5	9
156	Assay optimisation and technology transfer for multi-site immuno-monitoring in vaccine trials. PLoS ONE, 2017, 12, e0184391.	2.5	8
157	â€œ<i>It seems impossible that itâ€™s been made so quickly</i>â€ a qualitative investigation of concerns about the speed of COVID-19 vaccine development and how these may be overcome. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	3.3	8
158	Using Data from Macaques To Predict Gamma Interferon Responses after Mycobacterium bovis BCG Vaccination in Humans: a Proof-of-Concept Study of Immunostimulation/Immunodynamic Modeling Methods. Vaccine Journal, 2017, 24, .	3.1	7
159	A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates. Npj Vaccines, 2021, 6, 3.	6.0	7
160	Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults. Vaccines, 2021, 9, 396.	4.4	7
161	Rapid research response to the COVID-19 pandemic: perspectives from a National Institute for Health Biomedical Research Centre. Health Research Policy and Systems, 2022, 20, 24.	2.8	7
162	Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 1741-1751.	3.3	6

#	Article	IF	Citations
163	Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status. Tuberculosis, 2016, 96, 37-43.	1.9	6
164	Human Immunology of Tuberculosis. , 2017, , 213-237.		6
165	Targeting Phenotypically Tolerant<i>Mycobacterium tuberculosis</i>. , 0, , 317-360.		6
166	Equity for excellence in academic institutions: a manifesto for change. Wellcome Open Research, 2021, 6, 142.	1.8	6
167	Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. Vaccine, 2022, 40, 3484-3489.	3.8	6
168	Tuberculosis vaccines: present and future. Expert Review of Respiratory Medicine, 2008, 2, 721-738.	2.5	5
169	Tuberculosis vaccine promises sterilizing immunity. Nature Medicine, 2011, 17, 1185-1186.	30.7	5
170	A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity. Trials in Vaccinology, 2012, 1, 27-35.	1.2	5
171	Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. , 0, , 295-316.		4
172	Mouse and Guinea Pig Models of Tuberculosis. , 2017, , 143-162.		4
173	High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation. Scientific Reports, 2021, 11, 12274.	3.3	4
174	Preclinical Efficacy Testing of New Drug Candidates. , 0, , 269-293.		3
175	Evolution of<i>Mycobacterium tuberculosis</i>: New Insights into Pathogenicity and Drug Resistance. , 0, , 495-515.		3
176	The Minimal Unit of Infection:<i>Mycobacterium tuberculosis</i>in the Macrophage. , 0, , 635-652.		3
177	Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen. Vaccine, 2020, 38, 1241-1248.	3.8	3
178	Lessons from the first clinical trial of a non-licensed vaccine among UgandanÂadolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A. Wellcome Open Research, 2018, 3, 121.	1.8	3
179	A large National Institute for HealthÂResearch (NIHR) Biomedical Research Centre facilitates impactful cross-disciplinary and collaborative translational research publications and research collaborationÂnetworks: a bibliometric evaluation study. Journal of Translational Medicine, 2021, 19, 483.	4.4	3
180	Tuberculosis Diagnostics: State of the Art and Future Directions. , 0, , 361-378.		2

#	Article	IF	Citations
181	Acid-Fast Positive and Acid-Fast Negative<i>Mycobacterium tuberculosis</i>: The Koch Paradox. , 0, , 517-532.		2
182	Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions. , 0, , 533-539.		2
183	Metabolic Perspectives on Persistence. , 2017, , 653-669.		2
184	The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Research, 2021, 10, 257.	1.6	2
185	VALIDATE: Exploiting the synergy between complex intracellular pathogens to expedite vaccine research and development for tuberculosis, leishmaniasis, melioidosis and leprosy. F1000Research, 2018, 7, 485.	1.6	2
186	Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study. Scientific Reports, 2022, 12, 7808.	3.3	2
187	Global progress in tuberculosis vaccine development. Clinical Medicine, 2012, 12, s17-s20.	1.9	1
188	Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. International Journal of Epidemiology, 2016, 45, 580-580.	1.9	1
189	Clinical Testing of Tuberculosis Vaccine Candidates. , 2017, , 193-211.		1
190	The Immune Interaction between HIV-1 Infection andMycobacterium tuberculosis. , 2017, , 239-268.		1
191	Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control. , 2017, , 389-410.		1
192	Epigenetic Phosphorylation Control of<i>Mycobacterium tuberculosis</i>Infection and Persistence. , 0, , 557-580.		1
193	DNA Replication in Mycobacterium tuberculosis. , 2017, , 581-606.		1
194	The Sec Pathways and Exportomes of Mycobacterium tuberculosis. , 2017, , 607-625.		1
195	The Role of ESX-1 in Mycobacterium tuberculosis Pathogenesis. , 2017, , 627-634.		1
196	Regulation of Immunity to Tuberculosis. , 2017, , 73-93.		1
197	Phenotypic Heterogeneity in<i>Mycobacterium tuberculosis</i>. , 0, , 671-697.		1
198	The Memory Immune Response to Tuberculosis. , 2017, , 95-115.		1

#	Article	IF	Citations
199	Pathology of Tuberculosis: How the Pathology of Human Tuberculosis Informs and Directs Animal Models. , 0, , 117-129.		1
200	Ten minutes with Professor Helen McShane, Director, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust. BMJ Leader, 2020, 4, 96-97.	1.5	1
201	Need for more TB vaccine field sites. Indian Journal of Experimental Biology, 2009, 47, 445-6.	0.0	1
202	Clinical Evaluation of New Immunisation Strategies for Enhancing T Cell Responses against <i>M. Tuberculosis</i>. Clinical Science, 2003, 104, 51P-51P.	0.0	0
203	Investigating the Induction of Vaccine-Induced Th17 and Regulatory T Cells in Healthy,<i>Mycobacterium bovis</i>BCG Immunized Adults Vaccinated with a New Tuberculosis Vaccine, MVA85A. Vaccine Journal, 2011, 18, 696-696.	3.1	0
204	Tuberculosis vaccine trials â€“ Authors' reply. Lancet, The, 2013, 381, 2254.	13.7	0
205	From AIDS to TB vaccines â€" A career in infectious diseases and translational vaccinology. Human Vaccines and Immunotherapeutics, 2016, 12, 5-7.	3.3	0
206	Innate Immune Responses to Tuberculosis. , 2017, , 1-31.		0
207	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. , 2017, , 379-388.		0
208	The Role of Host Genetics (and Genomics) in Tuberculosis. , 2017, , 411-452.		0
209	The Evolutionary History, Demography, and Spread of the Mycobacterium tuberculosis Complex. , 2017, , 453-473.		0
210	Impact of Genetic Diversity on the Biology ofMycobacterium tuberculosisComplex Strains. , 2017, , 475-493.		0
211	Killing Mycobacterium tuberculosis In Vitro: What Model Systems Can Teach Us. , 2017, , 541-556.		0
212	Mycobacterium tuberculosisin the Face of Host-Imposed Nutrient Limitation. , 2017, , 699-715.		0
213	Animal Models of Tuberculosis: An Overview. , 2017, , 131-142.		0
214	Non-Human Primate Models of Tuberculosis. , 0, , 163-176.		0
215	Experimental Infection Models of Tuberculosis in Domestic Livestock. , 2017, , 177-191.		0
216	Tuberculosis Vaccines. , 2021, , 49-58.		0

#	Article	IF	Citations
217	The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells. F1000Research, 2021, 10, 257.	1.6	0
218	A New Vaccine for Tuberculosis: The Challenges of Development and Deployment. , 2009, , 63-72.		0
219	Challenges in Developing a Controlled Human Tuberculosis Challenge Model. Current Topics in Microbiology and Immunology, 2022, , 1.	1.1	0